Keppra

Developed for: cervical dystonia · Alzheimer disease · epilepsy · epilepsy with generalized tonic-clonic seizures
Investigated by: University of South Florida

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Label expansions (8)	US (FDA)	KEPPRA	—	2005-06-21 – 2019-10-23	fda.gov ↗
Approved	EU (EMA)	Keppra	—	2000-09-29	europa.eu ↗
Approved	US (FDA)	KEPPRA	—	1999-11-30	fda.gov ↗

today

US approved 1999

EU approved 2000

NCT00760318 · Ph 2

2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 21 trial
Phase 2	NCT00760318	Nov 2005 → Oct 2007	cervical dystonia	University of South Florida	Terminated	No outcome recorded Stop: Enrollment
Comparator or background therapy4 trials
Phase 4	NCT00510783 Comparator	Jul 2007 → Dec 2008	epilepsy with generalized tonic-clonic seizures	Emory University	Completed	No outcome recorded
—	NCT01685411 Background	Jan 2013 → Feb 2020	acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome	Masonic Cancer Center, University of Minnesota	Terminated	No outcome recorded
—	NCT01666080 Background	Aug 2012 → Jun 2027 expected	hemoglobinopathy, immunodeficiency disease	Masonic Cancer Center, University of Minnesota	Recruiting	No outcome recorded
—	NCT01554683 Comparator	Feb 2012 → Jul 2017	Alzheimer disease, epilepsy	Beth Israel Deaconess Medical Center	Completed	No outcome recorded

Every value below carries the sentence it was read from. 5 sources stand behind the page.

Field	Value	Cited text
Known as	Keppra	“Drug: Keppra” NCT01666080 ↗ 4 NCT01554683 ↗ NCT00760318 ↗ NCT01685411 ↗ NCT00510783 ↗
Route	Intravenous	“Patients in the intervention arm will receive IV Keppra” NCT00510783 ↗